Premium
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient‐level pooled analysis
Author(s) -
Chaudhuri Ajay,
Rosenstock Julio,
DiGenio Andres,
Meneghini Luigi,
Hollander Priscilla,
McGill Janet B.,
Dandona Paresh,
Ilgenfritz John,
Riddle Matthew
Publication year - 2012
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.1305
Subject(s) - insulin glargine , medicine , endocrinology , pioglitazone , type 2 diabetes , insulin , rosiglitazone , cholesterol , diabetes mellitus , lipid profile
Background The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods Patient‐level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18 years, diagnosed with type 2 diabetes for at least 6 months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL‐C, non‐HDL‐C, and triglycerides. Results Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL‐C ( p < 0.0003), 7.5% greater reduction in non‐HDL‐C ( p < 0.0001), and 7.8% greater reduction in total cholesterol ( p < 0.0001), whereas the HDL‐C increase with TZD was 7.6% greater than that with insulin glargine ( p < 0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs. Copyright © 2011 John Wiley & Sons, Ltd.